TITLE

2010 - Review: Target-oriented drug treatment improves clinical outcomes more than routine care in rheumatoid arthritis

AUTHOR(S)
Staud, Roland
PUB. DATE
September 2010
SOURCE
ACP Journal Club;9/21/2010, Vol. 153 Issue 3, p8
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents a study tracing the effectiveness of target-oriented drug treatments (TDTs)in the treatment of rheumatoid arthritis (RA). According to random control trials (RCTs) by M. Schoels and colleagues target-oriented drug treatments improves clinical outcomes compared with routine care recommended in RA. A chart presenting comparison for TDTs and routine treatment methods in RA, is also presented.
ACCESSION #
54115040

 

Related Articles

  • Abatacept: the evidence for its place in the treatment of rheumatoid arthritis. Köller, Marcus D. // Core Evidence;2007, Vol. 2 Issue 3, p163 

    Introduction: Rheumatoid arthritis (RA) is the most common inflammatory joint disease in adults with a prevalence of 0.5-1%. The development of targeted therapies, especially anti-TNF (tumor necrosis factor) treatment, has improved disease outcome during the last decade. But despite this...

  • Review: The addition of infliximab and etanercept to methotrexate is effective in the long term for rheumatoid arthritis.  // ACP Journal Club;Sept/Oct2007, Vol. 147 Issue 2, p42 

    The article presents information on a research that suggested that addition of infliximab (IFX) to methotrexate reduced symptoms and drug discontinuation in patients with rheumatoid arthritis (RA) in the long term. It is stated that etanercept (ETN) or IFX was compared in 30 patients with RA in...

  • Comparison of Treatment Strategies in Early Rheumatoid Arthritis. Goekoop-Ruiterman, Yvonne P. M.; de Vries-Bouwstra, Jeska K.; Allaart, Cornelia F.; van Zeben, Derkjen; Kerstens, Pit J. S. M.; Hazes, J. Mieke W.; Zwinderman, Aelko H.; Peeters, André J.; de Jonge-Bok, Johanna M.; Mallée, Constant; de Beus, Wim M.; de Sonnaville, Peter B. J.; Ewals, Jacques A. P. M.; Breedveld, Ferdinand C.; Dijkmans, Ben A. C. // Annals of Internal Medicine;3/20/2007, Vol. 146 Issue 6, p406 

    Background: In patients with early rheumatoid arthritis, initial combination therapies provide earlier clinical improvement and less progression of joint damage after 1 year compared with initial monotherapies (as demonstrated in the BeSt study). Objective: To evaluate whether the initial...

  • Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison. Baji, Petra; Péntek, Márta; Czirják, László; Szekanecz, Zoltán; Nagy, György; Gulácsi, László; Brodszky, Valentin // European Journal of Health Economics;May2014 Supplement, Vol. 15, p53 

    Objective: The aim of this meta-analysis was to compare the efficacy and safety of infliximab-biosimilar and other available biologicals for the treatment of rheumatoid arthritis (RA), namely abatacept, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, rituximab and tocilizumab....

  • Pipex Adds Late-Stage RA Drug to Bolster Autoimmune Pipeline. Boggs, Jennifer // BioWorld Today;8/20/2008, Vol. 19 Issue 162, p1 

    The article reports that the autoimmune disease portfolio of Pipex Pharmaceuticals Inc. was expanded by the addition of a rheumatoid arthritis (RA) drug, an oral heat-shock protein-derived peptide. The said drug presented good results in a Phase III trial in RA. The trial also found that the...

  • Prikaz bolesnika sa dugotrajnom remisijom reumatoidnog artritisa posle jednog ciklusa rituksimaba. Glišić, Branislava; Knežević, Bojana // Vojnosanitetski Pregled: Military Medical & Pharmaceutical Journ;Jan2012, Vol. 69 Issue 1, p78 

    Introduction. Rituximab selectively targets CD20+ B cells and presumably protects joints in rheumatoid arthritis. Complete remissions after a single treatment with rituximab, in some cases for longer than 1 year, are observed in only the minority of patients. We reported a patient suffering from...

  • Potential Role of Decoy B7-H4 in the Pathogenesis of Rheumatoid Arthritis: A Mouse Model Informed by Clinical Data. Azuma, Takeshi; Gefeng Zhu; Haiying Xu; Rietz, A. Cecilia; Drake, Charles G.; Matteson, Eric L.; Lieping Chen // PLoS Medicine;Oct2009, Vol. 6 Issue 10, p1 

    Background: A pathogenic hallmark of rheumatoid arthritis (RA) is persistent inflammatory responses in target tissues and organs. Immune responses mediated by T cells and autoantibodies are known to play pivotal roles. A possible interpretation for this observation is a loss of negative...

  • Arana to begin Second Phase II Trial of Lead Compound ART621.  // Australasian Biotechnology;Sep2008, Vol. 18 Issue 3, p123 

    The article reports on the plan of Arana Therapeutics® to start the second phase II trial of the lead compound ART621 for the treatment of rheumatoid arthritis by the end of 2008. The class of drugs is used for the treatment of inflammatory diseases and works by blocking the action of tumour...

  • Las terapias epigenéticas, más allá de los biológicos en el tratamiento de la artritis reumatoide.  // Reumatologia Clinica;nov/dic2010, Vol. 6 Issue 6, p306 

    No abstract available.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics